While the contribution of ezrin in Fas signalling has been extensively studied, little is known regarding TRAIL, with the exception of a recent study in which ezrin was proposed to impair both Fas ligand- and TRAIL-induced cell death in the tumor T-cell lymphoma cell line H9 [14]. Here, FAS is linked to T-cell non-Hodgkin lymphoma.